Linaclotide

لیناکلوتاید

⚠ Unverified

🍽️ Alimentary Tract And MetabolismGuanylate cyclase-C agonist

Market / country: 🇺🇸 USA

Linzess (US)

🧮 Dose calculator

Functional bowel / irritable bowel syndrome · Regimen source: FDA Linzess · 2.1

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

Formulations

👥 Special populations

  • 🤰 PregnancyUse with caution

    Darooyab: category C — only if benefit outweighs risk. Darooyab · G-5499/Linaclotide — مصرف در بارداری

    “مصرف در بارداری لیناکلوتاید گروه C در شرايط خاص و نظارت ويژه پزشك قابل استفاده است:”
  • 🤱 BreastfeedingNo specific problem stated

    Label: infant exposure not expected. FDA Linzess · 8.2

    “Maternal use of LINZESS is not expected to result in exposure to linaclotide or its active metabolite in breastfed infants.”
  • 👶 ChildrenUse with caution

    Label: contraindicated under 2 years (serious dehydration); approved for functional constipation from 2 y and IBS-C from 7 y. FDA Linzess · 4

    “LINZESS is contraindicated in: Patients less than 2 years of age due to the risk of serious dehydration”
  • 👴 Older adultsUse with caution

    Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Linzess · 8.5

    “In general, dose selection for an elderly patient should be cautious reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy.”
  • ⚥ Females & males of reproductive potentialNo data

    The source for this drug has no section for this group.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

🔗 Similar drugs

Doz is only a support tool and does not replace clinical judgment or official sources. Check every dose against the original source before prescribing. About & disclaimer · Sources

Inspired by the Saphira project; part of the content is taken from it.

Contact and correction requests — Telegram: @cenaav